Guidelines for an optimal management of a malignant colorectal polyp. What is essential in a pathology report ?

degree of invasion depth invasion lymphovascular permeation malignant polyp micropapillary risk factors tumour budding

Journal

Acta gastro-enterologica Belgica
ISSN: 1784-3227
Titre abrégé: Acta Gastroenterol Belg
Pays: Belgium
ID NLM: 0414075

Informations de publication

Date de publication:
Historique:
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 22 10 2020
Statut: ppublish

Résumé

Colorectal cancer (CRC) has become the most common malignancy in our country. Routine screening colonoscopy is on the rise. With the recent advances in endoscopic treatment, many T1 colorectal carcinomas are now found and their percentage amenable to endoscopic resection has increased. Endoscopists and pathologists dealing with the steadily increasing number of excised colorectal polyps have to collaborate closely to optimize patient care. Therapeutic management of patients after endoscopic resection is based on precise histological criteria that determine the risk of metastasis and the need for complementary surgery. This paper summarizes the procedures for the macroscopic management of endoscopic excisions and presents the identified risk factors which should be included in a standardized pathology report.

Identifiants

pubmed: 32233272

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-59

Informations de copyright

© Acta Gastro-Enterologica Belgica.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest

Auteurs

H Dano (H)

Department of Pathology, Cliniques Universitaires St Luc, UCL, Brussels, Belgium.

P Baldin (P)

Department of Pathology, Cliniques Universitaires St Luc, UCL, Brussels, Belgium.

P Demetter (P)

Department of Pathology, Institut Jules Bordet, Université libre de Bruxelles (ULB), Brussels, Belgium.

A Driessen (A)

Department of Pathology University Hospital Antwerp, University Antwerp, Edegem, Belgium.

A Hoorens (A)

Department of Pathology, University Hospital Ghent, Ghent, Belgium.

X Sagaert (X)

Department of Pathology, KUL, Leuven.

J Van Huysse (J)

Department of Pathology, AZ Sint Jan, Brugge, Belgium.

L Verset (L)

Department of Pathology, Institut Jules Bordet, Université libre de Bruxelles (ULB), Brussels, Belgium.

A Jouret-Mourin (A)

Department of Pathology, Cliniques Universitaires St Luc, UCL, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH